Xeris Biopharma Holdings, Inc.
- XERS
- NASDAQ
- Biotechnology
- Endocrinology Therapies
- Ready-to-Administer Injectables
$10.52
Today +1.99%Quote Oct 19, 2026, 02:00 PM UTC
+26.35%over the last month
Max drawdown −9.0%From 1-month high −1.6%3 months +19.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.92B
Quote Oct 19
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$15.00
+42.7% from here
Floor
$10.07
4.3% below price
Where the price sits
11 analysts
Analyst range, low to high
$14.00$16.00
- Price $10.52
- Resistance $10.55–$10.65
- Consensus $15.00
The price is right under resistance. Analysts' average target sits about 43% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about XERSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $102.7M
- Product$91.0M88.6%
- Keveyis$11.7M11.4%
Industry
Biotechnology
Employees
435
Founded
2005